Statin use and risk of PCa biochemical recurrence after radical prostatectomy.

[pjoshea13]

New study below [1].

"In the largest reported surgical cohort to date, we investigated the effect of statin therapy on BCRF {biochemical recurrence free} and overall survival in patients with CaP who have undergone radical prostatectomy (RP)."

"We performed a retrospective analysis of men (n = 3,088) participating in the NCI funded Specialized Program of Research Excellence (SPORE) in CaP at Northwestern University (NM) in Chicago, Illinois. Patients were treated with RP between 2002 and 2015. Patients in the statin users group received treatment within 2 years prior to or subsequent to RP."

"The analysis identified 1,222 statin users and 1,865 nonusers (mean age 71 years, 92% Caucasian).

"After a median follow-up time of 49.0 months, the 5-year BCRF survival rate was 93.3% ... among statin users and 88.6% ... among nonusers ...

"After 10 years, the progression-free survival (PFS) was 91.7% ...) among statin users and 86.5% ... among nonusers ..."

Statins did not improve overall survival.

"Given the known cardiovascular benefits of statins, we also examined various cardiovascular outcomes in RP statin users vs. nonstatin users ... Statin use was signifcantly associated with acute coronary syndrome and strokes ..."

Presumably related to the conditions that led to statin use, rather than directly due to statin use???

"... there was no statistically significant difference in pulmonary embolism or deep venous thrombosis events between the 2 groups."

-Patrick

[1] pubmed.ncbi.nlm.nih.gov/331...

Urol Oncol

. 2020 Oct 29;S1078-1439(20)30464-6. doi: 10.1016/j.urolonc.2020.09.027. Online ahead of print.

Statin use and risk of prostate cancer biochemical recurrence after radical prostatectomy

Nicole Prabhu 1 , Navina Kapur 2 , William Catalona 3 , Robin Leikin 4 , Irene Helenowski 5 , Borko Jovanovich 5 , Michael Gurley 6 , Tochi M Okwuosa 7 , Timothy M Kuzel 8

Affiliations collapse

Affiliations

1 Department of Internal Medicine, Rush University Medical Center, Chicago, IL.

2 Department of Internal Medicine, Rush University Medical Center, Chicago, IL. Electronic address: [e-mail].

3 Department of Urology, Northwestern University, Chicago, IL.

4 Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago, IL.

5 Department of Preventative Medicine, Northwestern University, Chicago, IL.

6 Northwestern University Clinical and Translational Sciences Institute, Chicago, IL.

7 Division of Cardiology, Department of Internal Medicine, Rush University Medical Center, Chicago, IL.

8 Division of Hematology/Oncology/Cell Therapy, Department of Internal Medicine, Rush University Medical Center, Chicago, IL.

PMID: 33132024 DOI: 10.1016/j.urolonc.2020.09.027

Abstract

Background: Multiple studies have investigated the role of statins in prostate cancer (CaP), the leading cause of cancer related death in men. Retrospective cohort studies investigating the correlation between statin use and biochemical recurrence free (BCRF) survival in men with CaP have been inconclusive.

Objectives: In the largest reported surgical cohort to date, we investigated the effect of statin therapy on BCRF and overall survival in patients with CaP who have undergone radical prostatectomy (RP).

Patients and methods: We performed a retrospective analysis of men (n = 3,088) participating in the NCI funded Specialized Program of Research Excellence (SPORE) in CaP at Northwestern University (NM) in Chicago, Illinois. Patients were treated with RP between 2002 and 2015. Patients in the statin users group received treatment within 2 years prior to or subsequent to RP. Wilcoxon rank-sum and Fisher's exact tests were used to compare age, race, Gleason score, clinical staging, and pathological stage between statin users and nonstatin users.

Results: The analysis identified 1,222 statin users and 1,865 nonusers (mean age 71 years, 92% Caucasian). After a median follow-up time of 49.0 months, the 5-year BCRF survival rate was 93.3% (95% confidence interval [CI]: 91.9-94.8%) among statin users and 88.6% (95% CI: 87.1%-90%) among nonusers (log-rank P< 0.001). After 10 years, the progression-free survival (PFS) was 91.7% (95% CI: 90.1%-93.3%) among statin users and 86.5% (95% CI: 84.4%-88.2%) among nonusers (log-rank P< 0.001).

Conclusions: Extended follow-up data in this large surgical cohort show statin use improves BCRF but not overall survival in RP patients.

Keywords: Biochemical free survival; Prostate Cancer; Statin.

Copyright © 2020. Published by Elsevier Inc.

[cesces]

Glad that supports Dr. myers statin protocol

[Hidden]

Do we know what the patients died of? If statin use reduced PCa death but people who had to use statins had increased cardiac death it would be a positive for statins. Of course the data would need to be adjusted to account for increased death from other causes, else the PCa death might appear lower than it actually is.

I cycle lovastatin with RYR (need to get a good brand that contains plenty of monacolin k).

Before I started a statin I took RYR as directed and also plant stanols/sterols as directed and my cholesterol dropped to a very low level.

ncbi.nlm.nih.gov/pmc/articl...

I take lovastatin since it was the only one I've found that doesn't give me terrible insomnia.

[pjoshea13 in reply to Hidden]

Odd that they looked at overall survival & cardio-related data but did not report on PCa mortality. Perhaps they didn't track cause of death.

You mention RYR & Lovastatin. There are those who believe that Lovastatin was initially discovered in RYR & should not have received a patent. When people started using RYR as an inexpensive source, there were efforts to ban RYR.

-Patrick

[Hidden in reply to pjoshea13]

The U.S. FDA banned therapeutic doses of RYR. I assume that this was supposedly "for our own good". Another toothless law. The brand I get works around that by recommending 4 tabs a day.

[Ramp7 in reply to Hidden]

I take this, "HPF Cholestene Red Yeast Rice". Two tablets each day. From my investigation it had one of the higher percentages of monacolin k. Since it is not regulated, each patch may have variations.

[Hidden in reply to Ramp7]

That's the brand I use. I take 0-6 tabs a day.

[Ramp7 in reply to Hidden]

0-6 tabs daily. I remember talking to Jane McLeland. She thought my dose was too low. Maybe I'll increase with a pulse approach. Noticed you have a blog. Shall check out.

[Hidden in reply to Ramp7]

I do lots of cycling. I figure it gives my liver/kidneys a break, gives my wallet a break, changes things up so it's harder for PCa to adapt, and allows me to push therapeutic doses of things.

[dhccpa in reply to Hidden]

I take HPF Cholestene RYR, which Consumer Lab said had the highest levels of Monoc K, although most brands had less than 10 years earlier.

What brand do you use?

[Hidden in reply to dhccpa]

HPF Cholestene RYR